Search Results

TRIANA Biomedicines, Inc. today announced that Dr. Patrick Trojer, President and Chief Executive Officer, will present at the UBS Biotechnology Private Company Virtual Symposium on Wednesday September 20, 2023 at 3:30 PM ET.

TRIANA Biomedicines, Inc. today announced the appointments of Dr. Vito Palombel as Chief Scientific Officer and Dr. Reza Mazhari as Chief Business Officer.

TRIANA Biomedicines, Inc. today announced that Dr. Patrick Trojer, President and Chief Executive Officer, will present at UBS Virtual Biotechnology Private Company Symposium on Thursday September 22, 2022 at 4:00 PM ET.

TRIANA Biomedicines, Inc. announced the addition of Robert A. Copeland, PhD, and Adrian M. Senderowicz, MD to its Scientific Advisory Board.

Innovent Biologics, Inc. provided interpretation and updates on clinical data from Mazdutide’s GLORY-1 study and its general biomedicine pipeline at an investor conference call on June 25.

A premier, target-first and rational molecular glue discovery platform to identify preferred E3 ligases for priority disease targets Series A will fund activities to identify multiple, rationally designed molecular glue clinical candidates Dr. Patrick Trojer joined as President & CEO & Board Director TRIANA Biomedicines, Inc. announced their launch with $110 million in total funding to establish a best-in-class, scalable platform to discover and develop “molecular glues”.

Endeavor BioMedicines, Inc. today announced the closing of a $132.5 million Series C financing, including the conversion of a $5 million convertible instrument.

Sail Biomedicines, Inc. (“Sail”), a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Wendy Chung, M.D., Ph.D., has joined Sail’s Board of Directors.